MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. CEO Michael Castagna will host a webcasted Fireside Chat on December 13 at 11:00 AM ET to discuss the company's vision for 2022. Additionally, Castagna and CFO Steven B. Binder will hold 1x1 virtual investor meetings. The Fireside Chat will be available on the company's website and archived for replay. MannKind focuses on inhaled therapeutic products for endocrine and orphan lung diseases, with its lead product, Afrezza, being the only inhaled ultra-rapid acting insulin available in the U.S.

WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the Company’s Chief Executive Officer, Michael Castagna, PharmD, will be participating in a webcasted Fireside Chat discussing its vision for 2022 and Mr. Castagna and the Company’s Chief Financial Officer, Steven B. Binder will be conducting 1x1 virtual investor meetings.

The webcasted Fireside Chat will be available for viewing at 11:00 AM ET on Monday, December 13, 2021, on the Company's website at https://investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay.

To arrange a 1x1 meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/winter2021invreg.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

MANNKIND CONTACT:

Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

FAQ

What is the schedule for the Lytham Partners Winter 2021 Investor Conference for MannKind (MNKD)?

MannKind will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021.

When will the webcasted Fireside Chat with MannKind's CEO take place?

The Fireside Chat with CEO Michael Castagna is scheduled for December 13, 2021, at 11:00 AM ET.

Where can I watch the MannKind Fireside Chat?

The Fireside Chat can be viewed on MannKind's website and will also be archived for replay.

Who will be presenting at the MannKind investor meetings during the conference?

CEO Michael Castagna and CFO Steven B. Binder will conduct the 1x1 virtual investor meetings.

What products does MannKind (MNKD) focus on?

MannKind focuses on developing inhaled therapeutic products for patients with endocrine and orphan lung diseases, including the FDA-approved Afrezza.